2025-02-22T23:54:05-05:00 DEBUG: VuFindSearch\Backend\Solr\Connector: Query fl=%2A&wt=json&json.nl=arrarr&q=id%3A%22irk-123456789-138571%22&qt=morelikethis&rows=5
2025-02-22T23:54:05-05:00 DEBUG: VuFindSearch\Backend\Solr\Connector: => GET http://localhost:8983/solr/biblio/select?fl=%2A&wt=json&json.nl=arrarr&q=id%3A%22irk-123456789-138571%22&qt=morelikethis&rows=5
2025-02-22T23:54:05-05:00 DEBUG: VuFindSearch\Backend\Solr\Connector: <= 200 OK
2025-02-22T23:54:05-05:00 DEBUG: Deserialized SOLR response
Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer — follow up at 10 years

Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer — follow up at 10 years

Aim: The main aim of our paper is to contribute to objectification of currently widely discussed results of overall survival (OS), disease free survival (DFS) and time from relapse to tumor progression (TTP) in women with breast cancer. Methods: Forty consecutive patients fulfilling the eligibility...

Full description

Saved in:
Bibliographic Details
Main Authors: Cinek, P., Filip, S., Vaňásek, J., Měřička, P., Bláha, M., Zouhar, M.
Format: Article
Language:English
Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2007
Series:Experimental Oncology
Subjects:
Original contributions
Online Access:http://dspace.nbuv.gov.ua/handle/123456789/138571
Tags: Add Tag
No Tags, Be the first to tag this record!
id irk-123456789-138571
record_format dspace
spelling irk-123456789-1385712018-06-20T03:09:48Z Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer — follow up at 10 years Cinek, P. Filip, S. Vaňásek, J. Měřička, P. Bláha, M. Zouhar, M. Original contributions Aim: The main aim of our paper is to contribute to objectification of currently widely discussed results of overall survival (OS), disease free survival (DFS) and time from relapse to tumor progression (TTP) in women with breast cancer. Methods: Forty consecutive patients fulfilling the eligibility criteria were admitted to the study. Fifty-six women were included in the control group. All patients received 6 cycles of adjuvant intensive cyclic combined chemotherapy with epirubicin 150 mg/m2 and cyclophosphamide 1250 mg/m2 (EC) applied each 14 days. To overcome haematological toxicity transplantations of autologous peripheral blood progenitor cells (PBPCs) or whole blood enriched of PBPC were used. Results: We found statistically significant difference in OS regardless of the stage of the disease to the benefit of women treated by intensive cyclic EC chemotherapy when compared with the control group. In evaluation of DFS no statistically significant difference was found in survival between the control group and the group with all stages of the disease. TTP in women without relation to the stage was statistically significantly longer than in the control group. Conclusion: In our study intensive cyclic EC chemotherapy did not show better curative effect when compared with conventional dosage chemotherapy. Цель:объективизация широко обсуждаемых результатов по общей выживаемости (OВ), периода ремиссии (ПР) и продолжительности периода от рецидива к опухолевой прогрессии (ПРОП) у больных раком молочной железы. Методы: обследовано 40 больных, отвечающих установленным критериям отбора, и 56 здоровых женщин, составивших контрольную группу. У всех больных проведено 6 циклов адъювантной интенсивной циклической комбинированной химио­терапии (эпирубицин — 150 мг/м2 и циклофосфамид — 1250 мг/м2 (ЭЦ)), проводимой каждые 14 дней. Для преодоления гематологической токсичности применяли трансплантацию клеток-предшественников периферической крови (КППК) или цельной крови, обогащенной КППК. Результаты: выявлены статистически значимые различия в ОВ, не зависящие от стадии заболевания, у пациенток, получавших интенсивную циклическую химиотерапию ЭЦ, по сравнению с контрольной группой. При оценке ПР не выявлено статистически значимых различий выживаемости между контрольной группой и больными во всех стадиях заболевания. ПРОП у пациенток независимо от стадии заболевания статистически значимо выше, чем таковой контрольной группы. Выводы: по результатам исследования, интенсивная циклическая химиотерапия ЭЦ не имеет лечебных преимуществ по сравнению со стандартной дозовой химиотерапией. 2007 Article Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer — follow up at 10 years / P. Cinek, S. Filip, J. Vaňásek, P. Měřička, M. Bláha, M. Zouhar // Experimental Oncology. — 2007. — Т. 29, № 2. — С. 144–151. — Бібліогр.: 23 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/138571 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
language English
topic Original contributions
Original contributions
spellingShingle Original contributions
Original contributions
Cinek, P.
Filip, S.
Vaňásek, J.
Měřička, P.
Bláha, M.
Zouhar, M.
Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer — follow up at 10 years
Experimental Oncology
description Aim: The main aim of our paper is to contribute to objectification of currently widely discussed results of overall survival (OS), disease free survival (DFS) and time from relapse to tumor progression (TTP) in women with breast cancer. Methods: Forty consecutive patients fulfilling the eligibility criteria were admitted to the study. Fifty-six women were included in the control group. All patients received 6 cycles of adjuvant intensive cyclic combined chemotherapy with epirubicin 150 mg/m2 and cyclophosphamide 1250 mg/m2 (EC) applied each 14 days. To overcome haematological toxicity transplantations of autologous peripheral blood progenitor cells (PBPCs) or whole blood enriched of PBPC were used. Results: We found statistically significant difference in OS regardless of the stage of the disease to the benefit of women treated by intensive cyclic EC chemotherapy when compared with the control group. In evaluation of DFS no statistically significant difference was found in survival between the control group and the group with all stages of the disease. TTP in women without relation to the stage was statistically significantly longer than in the control group. Conclusion: In our study intensive cyclic EC chemotherapy did not show better curative effect when compared with conventional dosage chemotherapy.
format Article
author Cinek, P.
Filip, S.
Vaňásek, J.
Měřička, P.
Bláha, M.
Zouhar, M.
author_facet Cinek, P.
Filip, S.
Vaňásek, J.
Měřička, P.
Bláha, M.
Zouhar, M.
author_sort Cinek, P.
title Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer — follow up at 10 years
title_short Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer — follow up at 10 years
title_full Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer — follow up at 10 years
title_fullStr Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer — follow up at 10 years
title_full_unstemmed Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer — follow up at 10 years
title_sort intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (pbpc) or whole blood in high-risk breast cancer — follow up at 10 years
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate 2007
topic_facet Original contributions
url http://dspace.nbuv.gov.ua/handle/123456789/138571
citation_txt Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer — follow up at 10 years / P. Cinek, S. Filip, J. Vaňásek, P. Měřička, M. Bláha, M. Zouhar // Experimental Oncology. — 2007. — Т. 29, № 2. — С. 144–151. — Бібліогр.: 23 назв. — англ.
series Experimental Oncology
work_keys_str_mv AT cinekp intensivecyclicchemotherapyandtransplantationofautologousperipheralbloodprogenitorcellspbpcorwholebloodinhighriskbreastcancerfollowupat10years
AT filips intensivecyclicchemotherapyandtransplantationofautologousperipheralbloodprogenitorcellspbpcorwholebloodinhighriskbreastcancerfollowupat10years
AT vanasekj intensivecyclicchemotherapyandtransplantationofautologousperipheralbloodprogenitorcellspbpcorwholebloodinhighriskbreastcancerfollowupat10years
AT merickap intensivecyclicchemotherapyandtransplantationofautologousperipheralbloodprogenitorcellspbpcorwholebloodinhighriskbreastcancerfollowupat10years
AT blaham intensivecyclicchemotherapyandtransplantationofautologousperipheralbloodprogenitorcellspbpcorwholebloodinhighriskbreastcancerfollowupat10years
AT zouharm intensivecyclicchemotherapyandtransplantationofautologousperipheralbloodprogenitorcellspbpcorwholebloodinhighriskbreastcancerfollowupat10years
first_indexed 2023-10-18T21:18:46Z
last_indexed 2023-10-18T21:18:46Z
_version_ 1796152487473840128

Similar Items